Glutamate (Glu) is associated with excitotoxic cell damage. Memantine modulates the glutamate induced excitotoxicity in Alzheimer's disease (AD). No information is available as to the influence of memantine on in vivo brain glutamate levels.
Introduction
Glutamate (Glu) excitotoxicity through N-methyl-D-aspartic acid receptor (NMDAr) is a feature of Alzheimer's disease (AD) (Lipton, 2004) . Glutamate is the main excitatory neurotransmitter in hippocampal circuits (Ottersen, 1991) and the hippocampus, crucial for memory performance, is an early affected target in the course of AD. Memantine, an NMDAr antagonist, is an approved treatment of moderate to severe AD. The mechanism of memantine is based on the modulation of NMDAr stimulation by glutamate. Recent reports suggest that it is also effective in mild to moderate stages (Bakchine and Loft, 2007) .
Proton magnetic resonance spectroscopy ( 1 H-MRS) enables a non-invasive sampling of biochemical composition of the brain. Studies of hippocampal region show a reduction in Nacetylaspartate (NAA) levels (Schuff et al., 1997; Block et al., 2002) in AD patients as compared with normal controls. Some authors suggested that the decrease in NAA was a disease, but not age-related phenomenon, as they observed that NAA levels declined significantly with age in the frontal cortex, but not in the hippocampus (Chen et al., 2000) . Also reduction in cortical glutamate was reported in a few single voxel 1 H-MRS AD studies (Antuono et al., 2001; Hattori et al., 2002) , but the effects of memantine on in vivo hippocampal glutamate levels have not been examined. 
